Table 2.
Absolute numbers of the included studies.
| Study | Patient (No.) | Design | Time of scan | MRI | PET/CT | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Cut-off | Sen | Spe | Parameter | Cut-off | Sen | Spe | ||||
| An, Y 2015 | 20 | Retro | B & A (preoperative) | ΔLD | Reduction > 30%a | 0.33 | 0.82 | ΔSUV | Reduction > 30%c | 0.33 | 0.88 |
| ΔLD | Increase > 88.7%b | 0.67 | 0.94 | ΔSUV | Reduction > 80.6%b | 0.67 | 0.88 | ||||
| ΔADC | Increase > 22.1%b | 0.67 | 0.71 | ||||||||
| Choi, J 2010 | 41 | Pro | B & A (3 or 8 cycles) | ΔLD | Reduction > 30%a | 0.71 | 0.95 | ΔSUV | Reduction > 50%d | 0.86 | 0.38 |
| Kim, T 2014 | 56 | Retro | B & A (3 or 6 cycles) | ΔLD | Reduction > 50%b | 0.91 | 0.77 | ΔSUV | Reduction > 60%b | 0.91 | 0.73 |
| Pahk, K 2015 | 21 | Retro | B & A (3 or 4 cycles) | ΔLD | Reduction > 38%b | 0.71 | 0.71 | ΔSUV | Reduction > 69%b | 0.86 | 1.00 |
| Park, J 2011 | 32 | Retro | B & A (18–22 days) | ΔLD | Reduction > 30%a | 0.63 | 0.96 | ΔSUV | Reduction > 50%d | 1.00 | 0.63 |
| Park, S 2012 | 34 | Retro | B & A (3 or 6 cycles) | ΔADC | Increase > 55%b | 1.00 | 0.70 | ΔSUV | Reduction > 64%b | 1.00 | 0.78 |
| Pengel 2014 | 93 | Pro | B & A (1 or 3 cycles) | ΔLD | Reduction > 50%b | 0.86 | 0.58 | ΔSUV | Reduction > 50%b | 0.47 | 0.94 |
| Tateishi 2012 | 142 | Retro | B & A (2 cycles) | ΔLD | Reduction > 30%a | 0.46 | 0.86 | ΔSUV | Reduction > 30%c | 0.67 | 0.96 |
| ΔKep | Reduction > 63%b | 0.52 | 0.92 | ΔSUV | Reduction > 80%b | 0.70 | 0.96 | ||||
| Cho, N 2016 | 35 | Pro | B & A (1 cycles) | ΔtCho | Reduction > 61%b | 1.00 | 0.76 | ΔSUV | Reduction > 62%b | 0.67 | 1.00 |
| Amioka 2016 | 63 | NR | B & A (NR) | ΔLD | Reduction > 30%a | 0.70 | 0.85 | ΔSUV | NR | 1.00 | 0.53 |
| Chen 2004 | 16 | Retro | B & A (NR) | ΔLD | Reduction > 30%a | 0.90 | 0.17 | ΔSUV | Reduction > 50%d | 0.90 | 0.83 |
| ΔLD | Reduction > 63%b | 0.90 | 0.50 | ΔSUV | Reduction > 50%b | 0.90 | 0.83 | ||||
| Hieken 2013† | 88 | Pro | B & A (NR) | ΔLD | NR | 0.61 | 0.59 | ΔSUV | NR | 0.63 | 0.85 |
aCut-off set by pre-specified RECIST criteria; bcut-off set by ROC analysis; ccut-off set by pre-specified PRECIST criteria; dcut-off set by pre-specified EORTC criteria; B & A, at baseline and after NAC; Pro, prospective; Retro, retrospective; NR, not reported; ΔLD, change in longest diameter; ΔADC, change in apparent diffusion coefficient; ΔKep, change in transfer constant; ΔtCho, change in total choline-containing compounds; ΔSUV, change in standardised uptake values. †Study assessed axillary lymph node response to NAC.